US OptionsDetailed Quotes
BCLI250516C2000
- 0.00
- 0.000.00%
15min DelayClose May 14 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV75.44%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Brainstorm Cell Therapeutics Stock Discussion
Groundbreaking ALS Treatment Discovery: How Genetics May Predict NurOwn Therapy Success
Major FDA Progress: New Phase 3b Trial Brings NurOwn ALS Treatment Closer to Approval
Major FDA Progress: New Phase 3b Trial Brings NurOwn ALS Treatment Closer to Approval
Just
Brainstorm Cell Therapeutics Submits Ind Amendment to FDA, Paving the Way for Phase 3B Trial of Nurown® in ALS
BrainStorm Cell Slashes Losses by 33%, Secures FDA Agreement for Major ALS Trial
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
Brainstorm Cell Therapeutics Granted Compliance Extension From Nasdaq
No comment yet